Dabigatran etexilate G.L. Pharma: Uses, Dosage & Side Effects
A direct oral anticoagulant (DOAC) that inhibits thrombin to prevent blood clot formation, used for stroke prevention in atrial fibrillation and treatment of venous thromboembolism
Dabigatran etexilate G.L. Pharma is a direct oral anticoagulant (DOAC) containing the active substance dabigatran etexilate, a prodrug that is converted to its active form dabigatran after ingestion. Dabigatran is a direct thrombin inhibitor that prevents blood clot formation by blocking the enzyme thrombin (factor IIa). It is primarily prescribed to prevent stroke and systemic embolism in adults with non-valvular atrial fibrillation (AF), to treat and prevent recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the prevention of venous thromboembolism (VTE) after elective hip or knee replacement surgery. Unlike older anticoagulants such as warfarin, dabigatran does not require routine blood monitoring and has a specific reversal agent (idarucizumab) available for emergency situations.
Quick Facts: Dabigatran etexilate G.L. Pharma
Key Takeaways
- Dabigatran etexilate G.L. Pharma is a direct oral anticoagulant that works by directly inhibiting thrombin, preventing blood clots from forming. It is used to prevent stroke in atrial fibrillation, treat DVT/PE, and prevent blood clots after hip or knee replacement surgery.
- Unlike warfarin, dabigatran does not require routine INR monitoring, has fewer food interactions, reaches therapeutic levels within 1–2 hours, and has a specific reversal agent (idarucizumab/Praxbind) for emergency situations.
- Capsules must be swallowed whole and never opened, crushed, or chewed, as this can increase drug absorption by up to 75% and significantly raise the risk of serious bleeding.
- Kidney function must be assessed before starting treatment and monitored regularly (at least annually), as approximately 80% of dabigatran is excreted by the kidneys. The drug is contraindicated in severe renal impairment.
- Major drug interactions exist with P-glycoprotein inhibitors and inducers (ketoconazole, dronedarone, ciclosporin, rifampicin), and concurrent use with other anticoagulants or antiplatelet agents significantly increases bleeding risk.
What Is Dabigatran etexilate G.L. Pharma and What Is It Used For?
Dabigatran etexilate G.L. Pharma contains the active substance dabigatran etexilate, which belongs to a class of medications known as direct oral anticoagulants (DOACs), also referred to as non-vitamin K antagonist oral anticoagulants (NOACs). Specifically, dabigatran is classified as a direct thrombin inhibitor (DTI), distinguishing it from other DOACs such as rivaroxaban, apixaban, and edoxaban, which are factor Xa inhibitors. This medication is a generic version of the original brand-name product and contains the same active substance at the same strength and in the same pharmaceutical form.
Dabigatran etexilate itself is a prodrug, meaning it is pharmacologically inactive in its administered form. After oral ingestion, the drug is rapidly absorbed from the gastrointestinal tract and converted to its active form, dabigatran, through esterase-catalyzed hydrolysis in the plasma and liver. The active metabolite dabigatran is a potent, competitive, and reversible direct thrombin inhibitor. Thrombin (also known as factor IIa) is a central enzyme in the coagulation cascade that converts fibrinogen to fibrin, the structural protein that forms the mesh of a blood clot. By blocking thrombin’s active site, dabigatran prevents the conversion of fibrinogen to fibrin and thereby inhibits clot formation.
An important advantage of dabigatran’s mechanism is that it inhibits not only free thrombin circulating in the blood but also thrombin that is already bound to fibrin within an existing clot (clot-bound thrombin), as well as thrombin-induced platelet aggregation. This comprehensive inhibition of thrombin activity provides robust anticoagulation across multiple stages of the clotting process.
Dabigatran etexilate G.L. Pharma is approved for several clinical indications:
- Prevention of stroke and systemic embolism in atrial fibrillation: Adults with non-valvular atrial fibrillation (AF) who have one or more risk factors for stroke (such as prior stroke or transient ischemic attack, age 75 or older, heart failure, diabetes, or hypertension) may benefit from long-term anticoagulation with dabigatran. The landmark RE-LY trial demonstrated that dabigatran 150 mg twice daily was superior to warfarin in preventing stroke and systemic embolism, while dabigatran 110 mg twice daily was non-inferior to warfarin with significantly fewer major bleeding events.
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE): After an initial course of parenteral anticoagulation (typically with a low-molecular-weight heparin for at least 5 days), dabigatran can be used to treat acute DVT and PE. The RE-COVER and RE-COVER II trials demonstrated that dabigatran was non-inferior to warfarin for the treatment of acute venous thromboembolism, with a lower rate of clinically relevant bleeding.
- Prevention of recurrence of DVT and PE: Following initial treatment, dabigatran can be continued long-term to prevent recurrence of venous thromboembolism in patients who remain at risk. The RE-MEDY and RE-SONATE trials established dabigatran’s efficacy in this setting.
- Prevention of venous thromboembolism after elective hip or knee replacement surgery: Dabigatran is approved for thromboprophylaxis in adults who have undergone elective total hip replacement or total knee replacement surgery, reducing the risk of potentially fatal blood clots in the postoperative period. The RE-MODEL, RE-NOVATE, RE-NOVATE II, and RE-MOBILIZE trials established efficacy in this indication.
Unlike warfarin, which indirectly reduces coagulation by inhibiting the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X), dabigatran directly and reversibly binds to the active site of thrombin. This results in a more predictable anticoagulant effect with fixed dosing, no need for routine coagulation monitoring, fewer dietary restrictions, and a more rapid onset of action (peak effect within 1–2 hours compared to several days for warfarin).
What Should You Know Before Taking Dabigatran etexilate G.L. Pharma?
Contraindications
There are several absolute contraindications to the use of dabigatran etexilate. Understanding these is critical for safe use of the medication.
- Hypersensitivity: Do not take dabigatran if you are allergic to dabigatran etexilate or any of the other ingredients in the capsule (tartaric acid, acacia, hypromellose, dimethicone, talc, hydroxypropylcellulose).
- Severe renal impairment: Dabigatran is contraindicated in patients with a creatinine clearance (CrCl) below 30 mL/min (EMA guidelines). Because approximately 80% of dabigatran is eliminated by the kidneys, severe kidney impairment leads to dangerous accumulation of the drug and a significantly elevated bleeding risk.
- Active clinically significant bleeding: Do not take dabigatran if you have ongoing major bleeding, including gastrointestinal hemorrhage, intracranial bleeding, or any other active pathological bleeding.
- Lesions at risk of clinically significant bleeding: Conditions such as current or recent gastrointestinal ulceration, malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain or spinal surgery, recent ophthalmic surgery, recent intracranial hemorrhage, known or suspected esophageal varices, arteriovenous malformations, vascular aneurysms, or major intraspinal or intracerebral vascular abnormalities.
- Hepatic impairment or liver disease expected to impact survival: Significant liver disease can impair the prodrug conversion and alter coagulation parameters.
- Concomitant treatment with systemic ketoconazole, ciclosporin, itraconazole, or dronedarone: These are strong P-glycoprotein (P-gp) inhibitors that can dramatically increase dabigatran plasma levels, raising the risk of life-threatening bleeding.
- Mechanical prosthetic heart valves: Dabigatran must not be used in patients with mechanical prosthetic heart valves requiring anticoagulant therapy. The RE-ALIGN trial was stopped early due to an excess of thromboembolic events and bleeding in patients with mechanical heart valves treated with dabigatran compared to warfarin.
Warnings and Precautions
As an anticoagulant, dabigatran increases the risk of bleeding. Seek immediate medical attention if you experience signs of bleeding such as unusual bruising, blood in urine or stool, prolonged nosebleeds, bleeding gums, vomiting blood, black or tarry stools, dizziness, weakness, or unexplained swelling. In an emergency, the specific reversal agent idarucizumab (Praxbind) can rapidly reverse dabigatran’s anticoagulant effect.
Before and during treatment with dabigatran, the following precautions should be carefully considered:
- Renal function monitoring: Because dabigatran is predominantly eliminated by the kidneys, renal function (creatinine clearance) must be assessed before starting treatment. It should be reassessed at least annually in all patients, and more frequently (every 3–6 months) in patients over 75, in patients with known renal impairment, or in situations where renal function may decline (dehydration, concurrent nephrotoxic medications, acute illness).
- Surgical and invasive procedures: Dabigatran should be temporarily discontinued before planned surgery or invasive procedures to reduce bleeding risk. The timing depends on the procedure’s bleeding risk and the patient’s renal function. For procedures with a standard bleeding risk, stop dabigatran at least 24 hours before; for high-risk procedures or spinal/epidural anesthesia, stop at least 48 hours before (longer in patients with impaired kidney function).
- Spinal/epidural anesthesia or puncture: When neuraxial anesthesia or spinal puncture is performed, patients on anticoagulants including dabigatran are at risk of developing epidural or spinal hematoma, which can lead to long-term or permanent paralysis. The risk is increased by traumatic or repeated puncture and by use of epidural catheters.
- Age: Elderly patients (over 80 years) have an increased risk of bleeding and may require dose reduction. Patients aged 75–80 years should also be carefully assessed for bleeding risk.
- Body weight: Limited clinical data exist for patients weighing less than 50 kg. Consider a lower dose or closer monitoring in these patients.
- Gastrointestinal bleeding: Dabigatran has been associated with a higher rate of major gastrointestinal bleeding compared to warfarin, particularly in elderly patients. Patients with conditions that increase the risk of GI bleeding (such as recent GI ulceration, esophagitis, gastritis, or gastroesophageal reflux disease) should be monitored closely, and the benefit-risk balance should be reassessed regularly.
- Dyspepsia and gastritis: Gastrointestinal symptoms including dyspepsia, gastritis-like symptoms, and epigastric discomfort are among the most common adverse effects of dabigatran. Taking the capsules with food or a proton pump inhibitor may help reduce these symptoms.
Pregnancy and Breastfeeding
Dabigatran should not be used during pregnancy unless clearly necessary and the potential benefit justifies the potential risk to the fetus. Animal studies have shown reproductive toxicity, and the effect on human pregnancy has not been adequately studied. Women of childbearing potential should use effective contraception during treatment.
It is not known whether dabigatran is excreted in human breast milk, although animal studies have shown excretion in milk. A decision should be made whether to discontinue breastfeeding or to discontinue dabigatran therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman. As a precaution, breastfeeding is not recommended during treatment with dabigatran.
Never stop taking dabigatran without consulting your doctor. Abruptly discontinuing anticoagulation therapy in patients with atrial fibrillation significantly increases the risk of stroke and other thromboembolic events. If treatment must be stopped, your doctor will advise on appropriate transitional anticoagulation strategies.
How Does Dabigatran etexilate G.L. Pharma Interact with Other Drugs?
Dabigatran etexilate is a substrate of the P-glycoprotein (P-gp) efflux transporter. P-gp plays a crucial role in the absorption and renal elimination of dabigatran, which means that drugs that inhibit or induce P-gp can significantly alter dabigatran plasma levels. Unlike many other drugs, dabigatran is not significantly metabolized by cytochrome P450 (CYP) enzymes, which reduces the number of traditional drug-drug interactions but makes P-gp interactions especially important.
Major Interactions (Contraindicated)
| Drug | Type | Effect | Action |
|---|---|---|---|
| Ketoconazole (systemic) | Strong P-gp inhibitor | Increases dabigatran levels by 140–150% | Contraindicated |
| Dronedarone | Strong P-gp inhibitor | Increases dabigatran levels by approximately 70–100% | Contraindicated |
| Ciclosporin | Strong P-gp inhibitor | Significantly increases dabigatran levels | Contraindicated |
| Itraconazole | Strong P-gp inhibitor | Significantly increases dabigatran levels | Contraindicated |
Significant Interactions (Dose Adjustment or Caution Required)
| Drug | Type | Effect | Action |
|---|---|---|---|
| Amiodarone | Moderate P-gp inhibitor | Increases dabigatran levels by ~50% | No dose adjustment needed for AF; consider lower dose in VTE prophylaxis |
| Verapamil | Moderate P-gp inhibitor | Increases dabigatran levels by 12–180% depending on timing | Take dabigatran at least 2 hours before verapamil; dose reduction may be needed |
| Quinidine | Moderate P-gp inhibitor | Increases dabigatran levels by ~50% | Caution advised; consider dose reduction |
| Clarithromycin | P-gp inhibitor | May increase dabigatran levels by ~15–20% | Clinical monitoring advised |
| Rifampicin | Strong P-gp inducer | Reduces dabigatran levels by ~66% | Avoid concurrent use; loss of anticoagulant effect |
| Carbamazepine | P-gp inducer | Reduces dabigatran levels | Avoid concurrent use |
| St. John’s Wort | P-gp inducer | Reduces dabigatran levels significantly | Avoid concurrent use |
| Phenytoin | P-gp inducer | May reduce dabigatran levels | Avoid concurrent use |
Interactions with Anticoagulants and Antiplatelet Agents
Concurrent use of dabigatran with other anticoagulants or antiplatelet agents significantly increases the risk of bleeding. This includes warfarin and other vitamin K antagonists, low-molecular-weight heparins (enoxaparin, dalteparin), unfractionated heparin, fondaparinux, other DOACs (rivaroxaban, apixaban, edoxaban), and thrombolytic agents such as alteplase.
Antiplatelet agents including aspirin (acetylsalicylic acid), clopidogrel, prasugrel, ticagrelor, and non-steroidal anti-inflammatory drugs (NSAIDs) also increase bleeding risk when combined with dabigatran. In the RE-LY trial, concomitant aspirin use was associated with approximately double the risk of major bleeding compared to dabigatran alone. NSAIDs, particularly those with long half-lives, should be used with caution, and the shortest possible treatment duration is recommended.
Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) may also increase bleeding risk due to their antiplatelet effects. If combination therapy is clinically necessary, close monitoring for signs and symptoms of bleeding is essential.
Proton pump inhibitors (PPIs) such as omeprazole and pantoprazole may reduce dabigatran absorption by approximately 20–30% due to changes in gastric pH. However, this interaction is not considered clinically significant and no dose adjustment is required. PPIs may actually be helpful in reducing the gastrointestinal side effects commonly associated with dabigatran.
What Is the Correct Dosage of Dabigatran etexilate G.L. Pharma?
The dosage of dabigatran varies by indication, patient age, kidney function, and concurrent medications. The 75 mg capsule strength allows for dosage flexibility, particularly for patients who require dose reductions. Always follow your doctor’s specific instructions. The capsules must be swallowed whole with a glass of water and can be taken with or without food.
Adults – Stroke Prevention in Atrial Fibrillation
Standard Dose
150 mg taken twice daily (one capsule of 150 mg in the morning and one in the evening, approximately 12 hours apart). This dose demonstrated superiority over warfarin for stroke prevention in the RE-LY trial.
Reduced Dose
110 mg taken twice daily is recommended for: patients aged 80 years or older; patients taking concomitant verapamil (take dabigatran at least 2 hours before verapamil); and patients at higher bleeding risk as assessed by the physician. The 75 mg capsule can be combined with other strengths to achieve the prescribed dose.
Adults – Treatment of DVT and PE
Treatment Dose
150 mg taken twice daily, following at least 5 days of initial parenteral anticoagulation (e.g., low-molecular-weight heparin). Treatment duration is individualized based on the clinical situation, typically at least 3–6 months, and may be continued long-term if the benefit outweighs the bleeding risk.
Adults – VTE Prophylaxis After Hip or Knee Replacement
Knee Replacement
Starting dose: 110 mg taken 1–4 hours after surgery, then 220 mg once daily (two capsules of 110 mg) for a total of 10 days. For patients over 75 years, moderate renal impairment (CrCl 30–50 mL/min), or on verapamil: starting dose 75 mg, then 150 mg once daily.
Hip Replacement
Starting dose: 110 mg taken 1–4 hours after surgery, then 220 mg once daily for a total of 28–35 days. For patients over 75 years, moderate renal impairment (CrCl 30–50 mL/min), or on verapamil: starting dose 75 mg, then 150 mg once daily.
Elderly Patients
Elderly patients are at increased risk for both thromboembolic events and bleeding. For patients aged 75–80 years with atrial fibrillation, either 150 mg or 110 mg twice daily may be prescribed based on individual risk assessment. For patients aged 80 years and older, the recommended dose is 110 mg twice daily. In VTE prophylaxis after surgery, patients over 75 years should receive the reduced dose of 150 mg once daily (rather than 220 mg once daily).
Renal Impairment
For patients with moderate renal impairment (CrCl 30–50 mL/min), the dose for atrial fibrillation is 150 mg or 110 mg twice daily based on individual assessment of thromboembolic versus bleeding risk. In VTE prophylaxis after surgery, a reduced dose of 150 mg once daily is recommended. Dabigatran is contraindicated when CrCl is below 30 mL/min.
Missed Dose
If you miss a dose of dabigatran, take it as soon as you remember, provided there are at least 6 hours remaining before the next scheduled dose. If there are fewer than 6 hours until the next dose, skip the missed dose and take the next one at the regular time. Do not take a double dose to make up for a missed one. Forgetting to take doses can increase your risk of developing a blood clot.
Overdose
There is no general antidote for dabigatran overdose in the usual sense, but the specific reversal agent idarucizumab (Praxbind) is available and can rapidly neutralize the anticoagulant effect of dabigatran. In the event of overdose or accidental excessive dosing, seek immediate medical attention. Activated charcoal may be considered if ingestion occurred within the previous 2 hours, as it can reduce absorption. Dabigatran can also be removed by hemodialysis, although clinical experience is limited. Standard supportive measures such as surgical hemostasis and volume replacement should be employed as needed.
Dabigatran capsules must always be swallowed whole. Opening, crushing, or chewing the capsules removes the protective coating and can increase bioavailability by up to 75%, leading to a dramatically higher risk of serious and potentially life-threatening bleeding. Remove capsules from the blister pack only immediately before taking them.
What Are the Side Effects of Dabigatran etexilate G.L. Pharma?
Like all anticoagulant medications, dabigatran can cause side effects, although not everybody gets them. The most significant risk is bleeding, which is an expected pharmacological effect of any anticoagulant. The clinical trials that evaluated dabigatran (particularly the RE-LY, RE-COVER, and RE-MEDY trials) provide extensive safety data. In the RE-LY trial involving over 18,000 patients with atrial fibrillation, the rate of intracranial hemorrhage was significantly lower with dabigatran compared to warfarin, while gastrointestinal bleeding was somewhat higher with the 150 mg dose.
The side effects are listed below by frequency category according to the standard MedDRA classification used by the European Medicines Agency:
Common
May affect up to 1 in 10 people
- Gastrointestinal bleeding (stomach, intestinal, rectal, or hemorrhoidal bleeding)
- Abdominal pain or discomfort
- Dyspepsia (indigestion, heartburn, stomach discomfort)
- Nausea
- Diarrhea
- Gastritis-like symptoms (inflammation of the stomach lining)
- Gastro-esophageal reflux disease (GERD)
- Nosebleeds (epistaxis)
- Urogenital bleeding (blood in urine, excessive menstrual bleeding)
- Decreased hemoglobin or hematocrit (reduced red blood cell count)
- Skin bleeding (bruising, bleeding from a wound)
Uncommon
May affect up to 1 in 100 people
- Intracranial hemorrhage (bleeding in the brain)
- Thrombocytopenia (low platelet count)
- Hypersensitivity reactions (rash, itching)
- Hematoma (collection of blood under the skin)
- Traumatic bleeding (bleeding from injuries or surgical wounds)
- Hemoptysis (coughing up blood)
- Rectal bleeding
- Hemorrhoidal bleeding
- Esophageal ulcer
- Dysphagia (difficulty swallowing)
- Abnormal liver function tests or elevated liver enzymes
- Skin rash or pruritus (itching)
Rare
May affect up to 1 in 1,000 people
- Anaphylactic reaction (severe, potentially life-threatening allergic reaction)
- Angioedema (rapid swelling of the skin, mucous membranes, or both)
- Urticaria (hives)
- Bronchospasm
- Hepatic function abnormalities or jaundice
- Alopecia (hair loss)
Not Known
Frequency cannot be estimated from available data
- Neutropenia (low white blood cell count)
- Agranulocytosis (severely low white blood cell count)
Bleeding is the most important adverse effect of dabigatran. Major bleeding events occur in approximately 2–3% of patients per year in the atrial fibrillation setting. The risk of bleeding is influenced by patient age, renal function, body weight, concomitant medications, and the presence of comorbidities. In the landmark RE-LY trial, the 150 mg twice daily dose had similar major bleeding rates to warfarin but with significantly fewer intracranial hemorrhages, while the 110 mg twice daily dose had significantly lower major bleeding than warfarin.
Gastrointestinal symptoms, particularly dyspepsia, are among the most common reasons patients discontinue dabigatran. The tartaric acid core of the capsule formulation, which is essential for optimal absorption, is thought to contribute to these symptoms. Taking dabigatran with food or a proton pump inhibitor can help reduce GI discomfort without significantly affecting the drug’s efficacy.
If you experience any side effects, or if you notice any effects not listed here, tell your doctor or pharmacist. You can also report side effects directly via your national adverse drug reaction reporting system. By reporting side effects, you can help provide more information on the safety of this medicine.
Contact your doctor or go to the nearest emergency department immediately if you experience: black or tarry stools; blood in your urine (pink, red, or dark brown); coughing up or vomiting blood or material that looks like coffee grounds; severe headache, confusion, or sudden weakness (signs of intracranial bleeding); prolonged or uncontrollable bleeding; dizziness, lightheadedness, or fainting; or signs of a severe allergic reaction (swelling of face, lips, tongue, or throat; difficulty breathing or swallowing).
How Should You Store Dabigatran etexilate G.L. Pharma?
Proper storage of dabigatran is essential to maintain the medication’s effectiveness and safety. Dabigatran capsules are particularly sensitive to moisture, and incorrect storage can compromise the drug’s integrity.
- Temperature: Store below 30°C (86°F). Do not refrigerate or freeze.
- Moisture protection: Keep the capsules in their original blister packaging to protect from moisture. Do not remove capsules from the blister pack until you are ready to take them. The blister packing contains a moisture barrier that is critical for maintaining capsule integrity.
- Pill organizers: Do not transfer dabigatran capsules to pill organizers, weekly pill boxes, or other containers, as exposure to humidity can degrade the capsules and alter the drug’s bioavailability.
- Bottle packaging: If your dabigatran is supplied in a bottle, use all capsules within 4 months of first opening the bottle. Keep the bottle tightly closed.
- Children: Keep out of the sight and reach of children.
- Expiration date: Do not use this medicine after the expiry date stated on the carton, blister, or bottle. The expiry date refers to the last day of that month.
- Disposal: Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures help to protect the environment.
If you notice any change in the appearance of the capsules (such as discoloration, sticking together, or a different smell), do not use them and consult your pharmacist. Damaged or open capsules must not be taken, as the altered bioavailability could increase the risk of bleeding.
What Does Dabigatran etexilate G.L. Pharma Contain?
Understanding the composition of your medication is important, particularly if you have known allergies or sensitivities to specific pharmaceutical ingredients.
Active Substance
Each hard capsule contains 75 mg of dabigatran etexilate (as dabigatran etexilate mesilate). The mesilate salt form facilitates absorption and stability of the prodrug.
Inactive Ingredients (Excipients)
The capsule pellet core contains:
- Tartaric acid: Creates an acidic microenvironment around the drug pellets, which is essential for the dissolution and absorption of dabigatran etexilate regardless of the patient’s gastric pH. This is a critical excipient that contributes to the reliable bioavailability of the drug, though it may also be associated with gastric discomfort in some patients.
- Acacia (gum arabic): A natural gum used as a binding agent in the pellet formulation.
- Hypromellose (hydroxypropyl methylcellulose): Used as a coating material and binder in the pellet formulation.
- Dimethicone: An antifoaming agent that aids in the manufacturing process.
- Talc: Used as a glidant and anti-adherent in the formulation.
- Hydroxypropylcellulose: Used as a binding and film-forming agent.
The hard capsule shell contains hypromellose, carrageenan, potassium chloride, titanium dioxide (E171), and may contain colouring agents such as iron oxide yellow (E172) and/or indigo carmine (E132), depending on the capsule strength and appearance.
Printing ink on the capsule typically contains shellac, propylene glycol, and iron oxide black (E172).
The tartaric acid in dabigatran capsules serves an essential pharmacological purpose by ensuring consistent drug absorption. However, it is also thought to contribute to the gastrointestinal side effects (dyspepsia, gastritis-like symptoms) that are more commonly reported with dabigatran compared to other DOACs. Taking the capsules with food may help reduce these symptoms.
Frequently Asked Questions About Dabigatran etexilate G.L. Pharma
Dabigatran and warfarin are both anticoagulants (blood thinners), but they work through fundamentally different mechanisms. Warfarin inhibits the synthesis of vitamin K-dependent clotting factors (II, VII, IX, and X), requiring regular INR blood test monitoring and careful dietary management of vitamin K intake. Dabigatran directly inhibits thrombin (factor IIa), providing a more predictable anticoagulant effect without the need for routine monitoring. Dabigatran reaches its peak effect within 1–2 hours, while warfarin takes several days. Dabigatran also has a specific reversal agent (idarucizumab), whereas warfarin reversal requires vitamin K and/or prothrombin complex concentrate, which takes longer to take effect.
Moderate alcohol consumption does not directly interact with dabigatran’s mechanism of action. However, excessive alcohol use can increase the risk of bleeding by impairing platelet function and potentially causing liver damage that affects the coagulation system. Chronic heavy alcohol use can also damage the stomach lining, increasing the risk of gastrointestinal bleeding. It is generally advisable to limit alcohol intake while on anticoagulant therapy. Discuss your alcohol consumption with your doctor for personalized advice.
Unlike warfarin, dabigatran does not require routine coagulation monitoring (INR tests). However, your doctor will need to check your kidney function (creatinine clearance) before starting treatment and at least once a year thereafter, since dabigatran is predominantly eliminated by the kidneys. If your kidney function is impaired, or if you are over 75 years old, more frequent monitoring (every 3–6 months) may be necessary. Your doctor may also order blood tests to assess hemoglobin, liver function, or coagulation parameters in specific clinical situations.
Always inform your dentist or surgeon that you are taking dabigatran. For minor dental procedures (simple extractions, scaling), your dentist may advise skipping one dose or continuing as normal with local hemostatic measures. For more invasive dental procedures or surgeries, dabigatran typically needs to be stopped beforehand. The timing depends on the procedure’s bleeding risk and your kidney function: at least 24 hours for standard-risk procedures and at least 48 hours for high-risk procedures. In patients with impaired kidney function, longer discontinuation times are needed. Never stop or restart dabigatran without your doctor’s guidance.
Dabigatran etexilate G.L. Pharma is a generic version of dabigatran etexilate, which was originally developed and marketed as Pradaxa by Boehringer Ingelheim. Generic medications contain the same active substance, in the same dose and pharmaceutical form, and have been demonstrated to be bioequivalent to the originator product through rigorous testing and regulatory approval. This means that Dabigatran etexilate G.L. Pharma has the same therapeutic effect as Pradaxa. Your doctor or pharmacist may switch you between brand-name and generic versions based on availability and local prescribing practices.
Yes, dabigatran capsules can be taken with or without food. Food does not significantly affect the total amount of dabigatran absorbed, although it may delay the peak plasma concentration by approximately 2 hours. For patients who experience gastrointestinal side effects such as dyspepsia or stomach discomfort, taking dabigatran with food or a meal may help reduce these symptoms. The capsules should be taken with a full glass of water to aid swallowing and reduce the risk of esophageal irritation.
References
- European Medicines Agency (EMA). Dabigatran etexilate – Summary of Product Characteristics (SmPC). Accessed 2026.
- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation (RE-LY trial). N Engl J Med. 2009;361(12):1139-1151. doi:10.1056/NEJMoa0905561
- Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER trial). N Engl J Med. 2009;361(24):2342-2352. doi:10.1056/NEJMoa0906598
- Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis (RE-COVER II). Circulation. 2014;129(7):764-772. doi:10.1161/CIRCULATIONAHA.113.004450
- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612
- Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal – full cohort analysis (RE-VERSE AD). N Engl J Med. 2017;377(5):431-441. doi:10.1056/NEJMoa1707278
- Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves (RE-ALIGN trial). N Engl J Med. 2013;369(13):1206-1214. doi:10.1056/NEJMoa1300615
- World Health Organization (WHO). Model List of Essential Medicines – 23rd List, 2023. Geneva: WHO; 2023.
- Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants. Europace. 2021;23(10):1612-1676. doi:10.1093/europace/euab065
- British National Formulary (BNF). Dabigatran etexilate monograph. National Institute for Health and Care Excellence (NICE). Accessed 2026.
Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Cardiology, Hematology, and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent panel of board-certified physicians
Evidence Standard
Level 1A – Based on systematic reviews and meta-analyses of RCTs (RE-LY, RE-COVER, REVERSE-AD)
Guidelines Followed
EMA SmPC, FDA Label, ESC/EHRA Guidelines, ISTH Guidelines, BNF, WHO Essential Medicines List
Last reviewed: | Next review: December 2026 | This article has no commercial funding and no conflicts of interest. Meet our medical team.